Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis

Figure 1

Cell growth (left) and cell cycle (right) analysis of PC-3, DU-145 or LNCaP cells. Tumor cells were treated either with 1 μM AEE788, 1 mM VPA or 1 nM RAD001, or with all compounds simultaneously (triple drug), as indicated in the materials section. Controls remained untreated. Cells were counted after 24, 48 and 72 h using the MTT dye reduction assay. One representative experiment of six is shown. Cell cycle analysis was carried out after 24 h. The cell population at each specific checkpoint is expressed as percentage of the total cells analyzed. One representative experiment of three is shown. *indicates significant difference to controls, #indicates significant difference to single drug treatment.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us